Cybin (HELP) EBITDA Margin (2020 - 2024)

Cybin (HELP) reported EBITDA Margin of 86.96% for Q4 2024, down 95490.0% on a YoY basis from N/an in Q1 2024, and down 110.02% quarter-over-quarter from 867.94% in Q4 2023.

Cybin (HELP) EBITDA Margin (2020 - 2024) Analysis & Trends

Cybin has reported EBITDA Margin for 3 years, with the latest figure at 86.96% in Q4 2024.

  • For the quarter ending Q4 2024, EBITDA Margin fell 95490.0% year-over-year to 86.96%; the trailing twelve-month figure through Dec 2024 stood at 675.14% (changed N/A YoY), and the FY2021 full-year result was 3468.4%, changed N/A from the prior year.
  • EBITDA Margin for Q4 2024 stood at 86.96%, down from 867.94% in the prior quarter.
  • The five-year high for EBITDA Margin was 867.94% in Q4 2023, with the low at 504.98% in Q2 2020.
  • Historically, EBITDA Margin has averaged 92.0% across 3 years, with a median of 86.96% in 2024.
  • The largest YoY upside for EBITDA Margin was 95490 bps in 2024 against a maximum downside of 95490 bps in 2024.
  • Cybin's EBITDA Margin stood at 504.98% in 2020, then jumped by 272 bps to 867.94% in 2023, then tumbled by 110 bps to 86.96% in 2024.
  • The last three EBITDA Margin figures came in at 86.96% (Q4 2024), 867.94% (Q4 2023), and 504.98% (Q2 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -6.43%
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 38.10%
9 Abivax 91.96 Bn 91.96 Bn - -
10 Cybin 75.42 Mn 75.42 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 -86.96%
Dec 31, 2023 867.94%
Jun 30, 2020 -504.98%